Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127753541 | 12775354 | 1 | I | 20160914 | 20160923 | 20160923 | EXP | CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076360 | BRISTOL MYERS SQUIBB | 56.00 | YR | F | Y | 0.00000 | 20160923 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127753541 | 12775354 | 1 | PS | ORENCIA | ABATACEPT | 1 | Subcutaneous | 150 MG, QMO | U | 125118 | 150 | MG | SOLUTION FOR INJECTION | /month | |||||
| 127753541 | 12775354 | 2 | SS | CELEBREX | CELECOXIB | 1 | Unknown | 200 MG, UNK | U | 0 | 200 | MG | CAPSULE | ||||||
| 127753541 | 12775354 | 3 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, UNK | U | 0 | 50 | MG | |||||||
| 127753541 | 12775354 | 4 | SS | HYDROXYCHLOROQUINE | HYDROXYCHLOROQUINE | 1 | Unknown | 400 MG, QD | U | 0 | 400 | MG | QD | ||||||
| 127753541 | 12775354 | 5 | SS | METHOTREXATE. | METHOTREXATE | 1 | Subcutaneous | UNK, QWK | U | 0 | /wk | ||||||||
| 127753541 | 12775354 | 6 | SS | NAPROSYN | NAPROXEN | 1 | Unknown | 500 MG, BID | U | 0 | 500 | MG | BID | ||||||
| 127753541 | 12775354 | 7 | SS | RITUXAN | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 1 G, UNK | U | 0 | 1 | G | SOLUTION FOR INJECTION/INFUSION | ||||||
| 127753541 | 12775354 | 8 | SS | SIMPONI | GOLIMUMAB | 1 | Subcutaneous | 50 MG, QMO | U | 0 | 50 | MG | SOLUTION FOR INJECTION | /month | |||||
| 127753541 | 12775354 | 9 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Unknown | 500 MG, BID | U | 0 | 500 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127753541 | 12775354 | 1 | Rheumatoid arthritis |
| 127753541 | 12775354 | 2 | Rheumatoid arthritis |
| 127753541 | 12775354 | 3 | Rheumatoid arthritis |
| 127753541 | 12775354 | 4 | Rheumatoid arthritis |
| 127753541 | 12775354 | 5 | Rheumatoid arthritis |
| 127753541 | 12775354 | 6 | Rheumatoid arthritis |
| 127753541 | 12775354 | 7 | Rheumatoid arthritis |
| 127753541 | 12775354 | 8 | Rheumatoid arthritis |
| 127753541 | 12775354 | 9 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127753541 | 12775354 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127753541 | 12775354 | Abdominal pain | |
| 127753541 | 12775354 | Dizziness | |
| 127753541 | 12775354 | Drug ineffective | |
| 127753541 | 12775354 | Drug intolerance | |
| 127753541 | 12775354 | Nausea | |
| 127753541 | 12775354 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |